Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication

  • Aldeyra Therapeutics Inc ALDX announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629.
  • Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure.
  • ADX-629 and placebo were well tolerated, and no safety concerns were noted. 
  • Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder.
  • In addition to the statistical superiority of ADX-629 over the placebo in Romberg test balance time, flushing, and acetaldehyde, total cholesterol, and LDL levels were statistically lower following ADX-629 treatment than following placebo treatment. 
  • Aldeyra plans to initiate a Phase 2 trial of ADX-629 in moderate alcoholic hepatitis in 2023. Results from a Phase 2 trial of ADX-629 in chronic cough are expected in 1H of 2023, and results from Phase 2 clinical trials of ADX-629 in minimal change disease and Sjögren-Larsson Syndrome are expected in 2023.
  • Price Action: ALDX shares are up 0.96% at $6.28 on the last check Tuesday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!